Who makes TPD3310 injection?

TPD3310 injection is developed by TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD..

What development phase is TPD3310 injection in?

TPD3310 injection is in Phase 1.

Last reviewed 2026-04-19 · How we verify

TPD3310 injection

TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD. · Phase 1 active Small molecule

At a glance

Generic name	TPD3310 injection
Sponsor	TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of TPD3310 in Patients With Advanced Malignant Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TPD3310 injection CI brief — competitive landscape report
TPD3310 injection updates RSS · CI watch RSS
TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD. portfolio CI